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ABSTRACT
Pain associated with cancer is unpredictable and may reflect an inability to
quantify it in animals. We hypothesize that Conditioned Place Preference(CPP)testing
is sensitive to pain relieving drugs in animal models of cancer pain and that CPP scores
will reflect varying degrees of pain relief To test this, mice were assigned to one of four
groups: tumor or non-tumor groups conditioned to saline or morphine during preference
testing. After baseline preference testing in the CPP apparatus, animals received either
saline or morphine in the S+ chamber (initially non-preferred chamber). All animals
received saline in the S- chamber (initially preferred chamber). Preference scores for
non-tumor groups showed that mice receiving saline in both S+ and S- chambers show no
particular compartment preference, indicating that this apparatus and test procedure does
not show any compartment bias. For non-tumor animals administered morphine, the
preference score was higher than their saline control groups. We interpret this increase in
preference scores to be associated with morphine’s pleasurable side effects, which

are

known to underlie its abuse. Tumor saline mice also showed no particular compartment
preference. Mice with tumors administered morphine showed an increase in preference
scores over the last six trials prior to euthanasia. We interpret this increase in preference
scores to be due to the increasing amounts of pain associated with tumor growth. We
interpret that an increase in S+ compartment preference in tumor morphine animals
reflects drug-seeking behavior that was previously associated with pain relief in this
chamber. These findings show that CPP is capable of quantifying drug-seeking behavior
in tumor models.
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INTRODUCTION
Cancer is one ofthe leading causes of death and disability. With its limited
success in treatment, it remains a burgeoning problem for healthcare costs and
healthcare delivery. In North America alone, there were a total of638,300 deaths
just in 2008(American Cancer Society, 2011). A study done to assess the burden
of cancer found a total of20.5 disability-adjusted life years(DALY)for each
population of 1,000 cancer patients, with DALYs being defined as the years lost
due to premature death and disability (Fernandez de Larrea-Baz et. al., 2009).
Direct costs of health care, based on the services patients receive, are highest
shortly after diagnoses, ranging from $2,000 to $5,000 monthly (Yabroffet. al..
2011).
Ongoing research in oncology is aimed at targeting tumor detection,
growth and proliferation in cancer patients. From these studies, many promising
therapies have been established and include radiation, early detection increasing
survival, and chemotherapy. Radiation was found to result in a local control rate
of greater than 90 percent in patients with head and neck Merkel cell carcinoma
(Lawenda et. al., 2008). Frequent screening tests can detect cancer at earlier
stages when treatment is more effective(American Cancer Society, 2011).
Studies have shown that chemotherapy with fluorouracil with levamisole
improved the survival ofcolon cancer patients(Slevin and Payne, 2004). While
progress in these areas is being made, more research will be needed to combat this
illness.
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One aspect of cancer research that has not made much progress is the
management of pain associated with various cancers. Studies show that only 57
% of cancer patients are receiving the appropriate care for cancer related pain
(“Managing”, 2011). Traditional pain management approaches typically rely on
the use of opiates. While these drugs can alleviate some pain, they are not
without debilitating and undesirable side effects. Research has shown that use is
in fact associated with side effects; a study in 2009 showed 69 percent of
participants with at least one side effect such as nausea, headache, and anxiety,
among others(Manchikanti et. al., 2009). Collectively, these observations clearly
support the notion that development of novel approaches for treatment of pain
associated with cancer is warranted.
Advances in the treatment of any clinical syndrome are often dependent
on valid animal models that simulate the condition. Animal models with good
validity are homologous to four aspects of a given disease; etiology, symptom
profile, pathophysiological processes, and response to treatment. By
demonstrating the causes of a given disease and the body’s response to the
disease, as well as possible treatments, valid animal models enable researchers to
begin understanding cancer treatment and pain management in humans. There are
a number of animal models of cancer. These include: murine breast cancer
models(Liao et al. 2011), intravital microscopy for the study oftumors in mice
models(Baron et al. 2011), cancer immunotherapy in mice(Woller et al. 2011),
among others. However, all ofthese models primarily focus on
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pathophysiological processes and response to treatment in relation to tumor
growth and proliferation rather than management of pain associated with tumors.
There are numerous rodent-based models ofcancer pain. These include:
bone cancer pain models, non-bone cancer pain models, cancer invasion pain
models, cancer chemotherapeutic-induced peripheral neuropathy models, and
spontaneous occurring cancer pain models (Pacharinsak and Beitz, 2008).
Assessment protocols rely on radiant heat paw-withdrawal test, the von Frey test,
and changes in spontaneous behavior. These first two tests involve exposing the
animal’s hind paw to thermal and mechanical stimulation while measuring the
withdrawal threshold. Exposing the animal to highly noxious stimuli has little
clinical relevance because pain in cancer patients is persistent and spontaneous.
Adopting a different set of protocols may be necessary to develop promising new
therapies for clinical conditions ofcancer pain.
Conditioned Place Preference is a commonly used procedure to study the
reinforcing properties of drugs, or the tendency ofthe animal to increasingly seek
the administered drugs. This paradigm involves the pairing of drugs with
environments with distinct stimulus cues. It is based on traditional learning
paradigms whereby animals prefer the environment previously paired with
reinforcing drugs. In its traditional use, the amount oftime the animal spends in
an environment paired with the positively reinforcing drug is reflective ofthe
drug abuse potential. The use ofthis paradigm has helped researchers determine
the abuse liability of illicit substances.
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Research has co-opted this paradigm for use in pain research and has
demonstrated that place preference can be used to quantify the relief ofchronic
pain via analgesic drugs. For example, Sufka(1994), sought to determine whether
CPP might assess the negatively reinforcing properties of morphine against
arthritic pain. Inflamed and non-inflamed rats received eight conditioned trials,
four to morphine or four to saline, and then were given six preference trials to the
chamber. Non-inflamed rats showed a place preference to morphine-paired
chamber, which is not surprising due to the reinforcing properties of morphine.
However, adjuvant inflamed rats showed a greater score to morphine-paired
chamber over that ofthe non-inflamed animals. These data demonstrate that
place preference is capable of quantifying the negatively reinforcing (behavior is
strengthened by removing aversive stimuli) properties of drugs against chronic
pain.

The observation that CPP can assess the affective properties of analgesic
drugs in chronic pain models has been generalized to another chronic pain model.
For example. King et al.,(2009)sought to examine whether CPP might assess the
negative reinforcing properties of various spinal drugs against neuropathic pain.
Rats with and without spinal nerve ligation(SNL)were administered spinal
adenosine, clonidine, conotoxin, lidocaine or saline paired with alternating
chambers on every other day and were then given preference trials to the
chamber. SNL rats showed place preference to the drug-paired chamber. Those
without SNL showed no preference. It is possible that this paradigm might
similarly be sensitive to pain relieving drugs in cancer pain models.
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The purpose ofthe present research is to explore whether Conditioned
Place Preference testing is sensitive to pain relieving drugs in animal models of
cancer pain, and we predict that increased CPP scores will reflect varying degrees
of pain relief in tumor animals.

Methods

Subjects

Forty female C57BI/6 mice(Charles River, Margate Kent, UK)were used.
Mice weighed 18 +/- 1.5 grams upon delivery. Twenty were designated control
mice; the remaining 20 were in the experimental group where tumor cells were
implanted. All were housed individually in climate-controlled environments at
19 +/- 2 degrees Celsius and given food and water as needed. The mice were
given one week for acclimatization and weighed daily, beginning with day zero
(defined as the day of tumor implantation). In addition, mice were palpated for
tumor size daily from day one ofthe experiment. The work was reviewed and
conducted in accordance with the provisions of Animals(Scientific Procedures)
Act 1986 and Institutional Ethical review committee.
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Tumor Implantation

Mice were tail marked the day prior to anesthesia and implantation for
identification and tracking. Mice were anesthetized in an induction chamber with
5% isoflurane in oxygen (5L/min.). Upon transferring them to a multi-mask
system, anesthesia was maintained at 2% isoflurane in oxygen. Mice were placed
ventral side up on a heating blanket The temperature ofthe heating blanket
ranged from 34.5 to 37.5°C. Eye ointment was applied. A 27 gauge pediatric
cannula was placed into the urethra and urine was gently drained. The bladder
was then rinsed with 50 pL of0.ImL hydrochloric acid(HCl)for 20 seconds.
HCl was removed and bladder was rinsed 50 pL of0.ImL potassium hydroxide
(KOH)for 20 seconds. This was followed by three washes with 0.9 %
physiological buffered saline. The bladder was completely emptied and ready for
tumor implantation. Syringes containing 50 pL ofthe tumor cell suspension
MB49LUC were inserted and secured to the tails using tape. The cells were left in
situ for 60 minutes. During this step, control mice are given saline instead.
Following implantation, the catheters were removed and mice were placed in an
incubator set at 24-26°C for 20 minutes, or until fully ambulatory.

Conditioned Place Preference

Conditioned place preference apparatus was supplied by Med Associates
model MED-CPP-MSAT. The apparatus consists ofthree sections; a neutral gray
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center compartment with a smooth floor, a black compartment with a stainless
steel grid floor, and a white compartment with a spaced stainless steel mesh floor.
Lights in each chamber and guillotine doors separating the chambers are operated
using a computer. CPP procedure involved three phases. First, the initial
compartment preferences for the mice were determined and designated the Schamber. The second phase involved training the mice with an S- trial in the
morning, where the mice received saline and were placed in their initially
preferred chamber. This was followed by an S+ trial in the afternoon, where mice
received their designated drug treatment and were placed in their initially non
preferred chamber. Non- tumor and tumor mice designated saline treatment
received saline for both trials. Non-tumor and tumor mice assigned morphine
treatment received saline in the morning and morphine in the afternoon. The third
phase was a 15-minute preference test trial. The second and third phases were
repeated until the mice reached the humane endpoint for euthanasia.
On day one, following tumor implantation, an initial 45-minute trial was
used to determine the baseline compartment preference. The mouse was placed in
the starting chamber(neutral gray chamber)for one minute prior to the lights
coming on and the doors opening. Time spent exploring the compartments was
used to calculate the initial black and white compartment preference, which was
designated the S- chamber. The morphine-designated chamber(S+) was assigned
to the chamber initially non-preferred by the mouse.
Upon determination of baseline compartment preference, the mice
underwent repeated sets of saline/morphine conditioning trials. All mice received
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saline in the morning to avoid any carryover effects from the morphine on the
afternoon trial. In the morning session, saline was administered subcutaneously
and the mouse was immediately placed into its preferred chamber as previously
determined. The doors remained closed and the mouse was confined for a 45minute period. The mice were then returned to their cages. For the afternoon
session, 2 mg/kg of morphine or saline was administered subcutaneously and the
mouse was immediately placed in the S+ non-preferred chamber. The doors
remained closed and the mouse was confined for 45 minutes and then returned to
its cage. Morning and afternoon training sessions took place for two consecutive
days.
The mice were tested on every third morning for chamber preference. The
mice received no drug treatment. They were placed into the start chamber for one
minute prior to the lights coming on and the doors opening. The mice remained
in the apparatus for 15 minutes. Time spent exploring the compartments was used
to calculate black and white compartment preference after conditioning trials two
days prior. Preference score was calculated by taking the total time spent in S+
chamber divided by the amount oftime spent in S+ plus S-. This three-day cycle
was continued until they reached the humane endpoint for euthanasia.

Tumor Detection

In order to quantify tumor growth and proliferation, mice were scanned
using 1 VIS (Caliper life Sciences/Xenogen). These scans were conducted
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immediately following place preference testing. Mice were injected with luciferin
IP and allowed a 10-minute adjustment period They were then anaesthetized in
groups of 5 in an induction chamber with 5% isoflurane in oxygen(5 L/min).
Mice were placed in I VIS scanner and anesthesia was maintained at 2.5%
isoflurane in oxygen. Images were then taken. All 20 cancerous mice and 5
randomly selected control mice were scanned following CPP testing. Mice were
allowed to recover from anesthesia and returned to their cages.

Thermal Nociceptive Testing

Nociceptive testing was designed to determine hyperalgesia associated
with tumors and the possibility of morphine analgesia on pain responses. Thermal
nociceptive testing was carried out using Hargreaves apparatus(Ugo Basile 37370
- Plantar Test). Mice were placed in a clear chamber and allowed time to
acclimate to environment. A movable infrared source was placed under the glass
floor directly beneath the animal’s hind left or right paw. Upon detection, a timer
was initiated and terminated when the mouse withdrew its paw. Paw withdrawal
latency was recorded 3 times each for each left and right hind paw. Hargreaves
testing was administered twice, with and without morphine, once the mice
reached the humane endpoint for euthanasia. After the baseline measure was
taken, mice were injected with 2 mg/kg of morphine subcutaneously and given 15
minutes before being tested again.
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Post Mortem

Euthanasia occurred when the following criteria were met: a large,
palpable tumor was present, more than 15% loss ofbody weight, and the presence
of haematuria. Mice were euthanized via rapid cervical dislocation upon meeting
these criteria. Following euthanasia, mice underwent a post mortem examination,
removing the bladder, kidneys, liver, and spleen. The weights ofall were
recorded and observations such as size, shape, and color were noted. Tumor
samples were stored at -80°C for further analysis.

RESULTS

Place Preference Scores

The effects of drug treatment and tumor treatment on place preference
score across the final six preference trials are summarized in Fig 1. Non-tumor
mice administered saline showed no preference to S+ or S- chambers across all
trials with a preference score ofaround 0.5. Non-tumor mice administered
morphine showed a slightly higher score in the S+ direction with scores steady
over all six trials. Tumor mice administered saline showed neither an S+ nor Spreference. Tumor mice given morphine showed a steadily increasing preference
to the S+ chamber across the last six trials prior to euthanasia. A 3-way betweenwithin ANOVA of these data revealed a marginally significant Drug Treatment
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effect, F(1,165)= 3.51, p = 0.07, a significant Preference Trial effect, F(5,165)=
2.51, p < 0.05 and a significant Tumor x Preference Trial interaction,F(5,165)=
2.81, p < 0.05. All other treatment main and interaction effects were not
significant.
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Figure 1: The effects of tumor x drug treatment on place preference score. The graph shows
the mean place preference scores on the last6 preference trials prior to euthanasia. Data
points represent means ± SEM,sample size N=8-10. Drug treatment effect was found to he
marginally significant, p=0.07. Preference trial effect and Tumor x Preference Trial
interaction also proved significant, p<0.05.

These findings prompted our calculating a change in place preference
scores from Preference Trial 6 to Trial 1 day before euthanasia and these data are
summarized in Figure 2. The change in preference for non-tumor mice given
saline was around 0.05. Non-tumor mice given morphine showed a change score
of -0.027. Tumor mice given saline showed a change score of0.035. Tumor
mice administered morphine showed the highest change score of0.161. A 2-way
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ANOVA of these data revealed a marginally significant Tumor Treatment effect,
F(l,33)= 3.13. p = 0.086 and a significant Tumor x Drug interaction term, F
(1,33)= 4.24, p < 0.05. However, additional analyses in the Tumor treatment
groups found only a marginally significant Drug treatment effect, F(l,15)= 2.86,
p = 0. 1 1.
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Figure 2: The effect of treatment groups on change in place preference scores between 6
days prior to euthanasia and the day before euthanasia. Data points represent means ±
SEM,sample size N=8-10. Data revealed a marginally significant Tumor Treatment effect,
p=0.086, and a significant Tumor x Drug interaction term, p<0.05. Analyses found only a
marginally significant Drug treatment effect, p=0.11.

Previous studies (Sufka et al., 2009) have suggested that variability in
tumor size (post-mortem) at study end-point may contribute to variance in
preference scores on day 1 before euthanasia. Therefore, separate regression
analyses were conducted on tumor weights and preference scores on Preference
Trial 1 for saline- and morphine-tumor conditions. Scatter plots for these data are
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provided in Fig 3a and b. For the saline group(Fig. 3a), regression analyses
revealed an r = 0.30, variance explained was 0.09 and this was not statistically
significant. For the morphine group (Fig. 3b), regression analyses revealed an r =
0.49 with variance explained equal to 0.24. While this latter finding was in the
predicted direction relative to the saline group, this regression analysis failed to
reach statistical significance, F(l,7)= 1.87, p = as.
Saline

>●

0.9

t!

0.8 -

£
O

0.7 -

r=0.30

2
(/I

0)
u

0.6 -

e

0.5.

a.

0.4 -

I
01

u

JS
a*

0.3

T

0

0.1

0.2

0.3

0.4

1

as

0.6

a?

TUmor Weight

Figure 3a: The relationship between tumor weight in saline conditioned mice and the place
preference score on the day prior to euthanasia. Data points represent means ± S£M.
Regression analysis showed no statistical significance, p=n.s.
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Regression analysis showed no statistical significance} p=n.s.

I VIS Scanning Scores

The amount of luciferin uptake in MB49 tumor cells, expressed as
photons/sec of the ATP and oxygen-dependent catalysis to oxy-luciferen, are
summarized in Figure 4 with I VIS scan examples in Figures 5 and 6. Data for
non-tumor groups are not shown as these mice failed to show any luciferin
uptake. There was no difference in luciferin uptake between mice administered
saline and those given morphine. The highest activity was shown on the last scan
day. Tumor progression was slow until the last day before euthanasia. A 2-way
ANOVA of these data (tumor groups only) revealed a significant treatment effect
for Scan Trial, F(5,65) - 2.31, p = 0.05. However, the Drug and Drug x Scan
Trial interaction terms were not significant.
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Peak luciferin uptake in MB49 tumor cells across all scan trials for
morphine and saline groups is summarized in Table 1. There is essentially no
difference in the mean uptake scores behveen both drug treatments. A 1-way
ANOVA of these data failed to reveal a significant treatment effect, F(l,15)=
0.38, p = n.s.

Saline

Morphine
Mean

273621250.000

175194222.222

Standard Deviation

397105938.238

248424241.572

8

9

Sample Size

Table 1: Peak luciferin uptake in IMB49 tumor cells across all scan trials for morphine and
saline groups. Data points expressed as photons/sec of the ATP and oxygen-dependent
catalysis to oxy-lucifercn. Data failed to reveal a significant treatment effect, p=n.s.
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To determine whether peak luciferin uptake in tumor cells predicts tumor
burden as measured by post-mortem tumor weight, regression analyses were
conducted in mice collapsed across saline- and morphine-tumor conditions.
Scatterplot for these data are provided in Figure?. Regression analyses revealed
an r = 0.26 with variance explained equal to 0.07. These analysis failed to reach
statistical significance, F(l,16)= 1.10, p = n.s.
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Figure 7: The relationship between tumor weight and peak luciferin uptake in MB49 tumor
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oxy-luciferen. Regression analysis failed to reach statistical significance, p=n.s.

Hargreaves Nociception Scores

Thermal nociceptive responses across all four treatment conditions pre and
post administration morphine are summarized in Fig 8. Response latencies were
normalized by using a square root transformation. Paw withdrawal latencies did
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not differ between tumor treatments with the exception ofthe non-tumor saline
group, showing a slightly lower mean score than the other three groups.
Morphine administration produced an increase in paw withdrawal latency across
all groups except for the non- tumor saline group, which remained the same.
Tumor animals show^ed the greatest increase in mean paw withdrawal latency.
with tumor- morphine having the highest increase. A 3-way between-within
ANOVA of these data revealed a significant Tumor Treatment effect, F(l,34)=
5.73, p = 0.02, a significant Drug Trial effect,?(1,34)= 4.14,p<0.05,a
significant Pre-Post Morphine Trial effect, F(1,34)= 11.57, p < 0.005 and a
significant Tumor x Pre-Post Morphine Trial interaction, F(1,34)= 4.28, p <
0.05. All other interaction terms were not statistically significant.
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Figure 8: The effect of morphine administration on thermal nociceptive responses across all
four treatment conditions. Data points expressed as paw withdrawal latency. Data points
represent means ± SEM,sample size N=8-10. Data revealed a significant Tumor Treatment
effect, p<0.05, a significant Drug Trial effect, p < 0.05,a significant Pre-Post Morphine Trial
effect, p < 0.005 and a significant Tumor x Pre-Post Morphine Trial interaction, p < 0.05.
All other interaction terms were not statistically significant.
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Discussion

The purpose ofthis research was to determine whether Conditioned Place
Preference testing is sensitive to pain relieving drugs in animal models ofcancer
pain. Place preference has been associated with quantifying reinforcing drug
properties. We predicted that tumor animals would show higher CPP scores to the
morphine chamber because it is associated with pain relief Four animal groups
were used to test this hypothesis: tumor and non-tumor groups of mice were
conditioned to either saline or morphine in a standard place preference procedure.
Place preference conditioning procedure was repeated on a three-day cycle,
whereby animals received a single S+/S- trial for two days and a preference test
on day three.
Preference scores for non-tumor groups showed that mice receiving saline
in both S+ and S- chambers show no particular compartment preference,
indicating that this apparatus and test procedure does not show any true
compartment bias. For non-tumor animals administered morphine,the preference
score was slightly higher than their saline control groups. We interpret this
increase in preference scores to be associated with morphine’s positively
reinforcing properties, which is known to underlie its abuse potential (Mattioli,
2012). Tumor mice receiving saline showed no compartment preference, further
confirming that the apparatus does not show any compartment bias.
Mice with tumors administered morphine showed an increase in
preference scores over the last six trials. We interpret that an increase in pain
levels due to tumor growth is to be accompanied by an increase in dmg seeking
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behavior by seeking the S+ chamber for pain relief We predicted that a test of
this interpretation would show that change in tumor growth over time would be
associated with a change in drug seeking behavior. Because ofthis, we posited
that variability in tumor size at euthanasia might reflect vaiying degrees of place
preference on the last day. This hypothesis was tested by plotting the tumor
weights against the place preference score on the last day. We found that control
groups along with tumor saline mice showed a small preference change. Tumor
mice given morphine showed a change in preference score three times larger than
the other groups. This proved to be consistent with the interpretation that CPP
scores are likely to change as disease progresses.
An additional measure in the present research was to plot tumor
progression using IVIS scanning technology. This was important because we are
unable to quantify tumor progression precisely and IVIS might be able to tell us
the point when morphine-seeking preference likely begins. Because tumor
induction and progression is highly variable across mice, it was necessaiy to plot
this progression through IVIS scanning. We believe that drug seeking behavior
may be altered in ways that relate to how large these tumors become. Drug
treatment showed no effect on tumor growth rate. Tumor progression was slow in
all tumor animals until the last day prior to euthanasia. Across all scan days,
luciferin uptake was highly variable. This variabihty may be related to dark fur
that likely affected the scans. It is possible to eliminate this variability by shaving
the mice or using albino mice. However, shaving the mice would cause an
increase in grooming and interfere with other measures ofthis research project
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(data not shown). Albino mice would not be ideal subjects because the C57BI/6
mice used in this study are especially susceptible to the tumor cell line used.
Even if all of these problems were solved, plotting tumor growth would still not
work because peak uptake in many mice preceded death by several scan days due
to the fact that tumors continue to grow but are unable to take up luciferin because
of diminished blood supply.
Most models of chronic pain rely on hyperalgesia to nociceptive stimuli as
the indicator of being in chronic pain. This is generally not the case for tumor
animals. For example, nociceptive response latencies showed that pre-morphine
mean scores did not differ to tumor exposure condition, thus illustrating that
hyperalgesia cannot be measured in this instance. Morphine administration
produced an increase in response scores across all groups except non- tumor
saline mice. In general, morphine does work to alter pain responses. Although,
we are uncertain of the reason non-tumor mice administered saline were
insensitive, this could be due to the small amount of morphine used during
Hargreaves testing. An amount of5-10 mg/kg probably would have given more
robust results than the 2 mg/kg of morphine actually used.
Assumptions that hyperalgesia is present in all tumor models to indicate
pain is incorrect. Hargreaves failed to show signs of hyperalgesia in mice with
bladder tumors; however, CPP did show that tumor mice do demonstrate behavior
of seeking pain relief as tumors progress. Thus, Conditioned Place Preference is
capable of measuring negative reinforcement(Sufka, 1994)not only in arthritic
and neuropathic models, but also tumor models.
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